Health Catalyst (HCAT) Announces Proposed $225M Share Offering

Health Catalyst, Inc. (“Health Catalyst”) (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the commencement of an underwritten public offering of $225.0 million of shares of its common stock. All of the shares in the offering are being sold by Health Catalyst. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Health Catalyst intends to grant the underwriters a 30-day option to purchase up to $33.75 million of shares of its common stock in the public offering at the public offering price.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and Evercore Group L.L.C. are acting as joint bookrunning managers for the proposed offering.

The proposed offering is being made pursuant to an effective shelf registration statement and prospectus and related preliminary prospectus supplement filed by the Company with the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the prospectus supplement and accompanying prospectus for this offering can be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at [email protected]; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at [email protected]; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at [email protected].

You May Also Be Interested In

• MDA Space raises $819M in share offering to fund CLS acquisition
• Goldman Sachs on JPMorgan (JPM): 'We believe the results were modestly positive'
• IBM misses Q2 targets as mainframe and software sales disappoint